EASDEndocrinology2022Updated 2022
ADA/EASD Consensus Report: Management of Hyperglycaemia in Type 2 Diabetes 2022
Published by European Association for the Study of Diabetes · 44 pages · Class I–II
6.5–8.0%HbA1c range
YesCV-driven choice
Class ISGLT2i for HF
Summary
Free previewJoint ADA/EASD consensus prioritises cardiovascular risk, heart failure, and CKD as drivers of drug choice over glycaemic control alone. GLP-1 RAs and SGLT2-i move to second-line regardless of HbA1c when CV disease, HF or CKD is present. Personalised HbA1c targets 6.5–8.0% based on patient profile.
Type 2 DiabetesGLP-1 RASGLT2iPersonalised targetsCV riskHbA1c
Key Recommendations
Evidence Grading & Drug Doses
What's New vs Previous Version
Implementation & Clinical Pearls
Full guideline access requires an account
Create a free Prognia account to read the complete guideline — including all recommendations, evidence tables, drug dosing, and clinical pearls.
Full guideline text with all recommendations
Evidence grades (Class I/II/III, Level A/B/C)
AI-generated summary and clinical pearls
Auto-logged as CPD/CME activity
Free plan includes 10 guideline reads per day · No credit card required